Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2023-02-02 Call Transcript
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on 31 January 2023, discussing the unaudited financial results for the quarter and nine months ended 31 December 2022. It includes detailed management commentary on business divisions, product performance, and future outlook. The presence of a moderator, management speakers, and Q&A format confirms it is a call transcript. The document is about 15,000 characters long, containing the full text of the call, not just an announcement or summary. Therefore, it fits the definition of a Call Transcript (CT).
2023-02-02 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges, submitting newspaper clippings of the extract of consolidated unaudited financial results for the quarter and nine months ended 31 December 2022. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relates to disclosure of material events. The document is brief (1207 characters) and does not contain detailed financial statements or analysis, but rather an announcement of published financial results in newspapers. This fits the profile of a Regulatory Filing (RNS) as it is a compliance disclosure and not the full financial report itself.
2023-02-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 31 January 2023 addressed to stock exchanges regarding the availability of the audio recording of the company's earnings conference call for the quarter and nine months ended 31 December 2022. It references the unaudited financial results and provides a link to the recording on the company's website. The document does not contain the transcript itself, nor detailed financial data, but merely informs about the availability of the audio recording. Given the short length (1082 characters) and the nature of the content, this is an announcement related to a call transcript rather than the transcript itself. Therefore, the appropriate classification is Call Transcript (CT) as it pertains to the earnings call content, but since it only announces the recording availability, it is best classified as Regulatory Filings (RNS) under the fallback rule for announcements that do not contain the full transcript or detailed financial data.
2023-01-31 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the unaudited financial results for the quarter and nine months ended 31 December 2022, including standalone and consolidated financial highlights, profitability analysis, business updates, and future outlook. It references the approval of these results by the Board of Directors and includes a press release with extensive financial data and operational commentary. The document is over 11,000 characters, indicating it is substantive and not merely a brief announcement. It contains actual financial figures, analysis, and business strategy, which aligns with the characteristics of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), nor is it just a press release or regulatory filing. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2023-01-31 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting held on 31 January 2023, where the Board approved the standalone and consolidated unaudited financial results for the quarter and nine months ended 31 December 2022. It includes detailed financial data such as revenue, expenses, profit before tax, tax expense, and segment-wise revenue and results. The presence of unaudited financial results for a quarter and nine months period indicates this is a quarterly/interim financial report. The document is about financial results for a period shorter than a full fiscal year and contains substantive financial data and analysis, not just a brief announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-01-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about an upcoming earnings conference call scheduled for January 31, 2023, following the announcement of unaudited financial results for the quarter and nine months ended December 31, 2022. It includes details for joining the call and contact information but does not contain any financial results or substantive financial data itself. The document is short (2134 characters) and serves as an announcement of the call rather than the call transcript or the earnings release. Therefore, it fits best under the category of Call Transcript (CT) announcements or related notifications. However, since it is only an intimation of the earnings conference call and not the transcript itself, the closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the call. Confidence is high due to clear mention of the call and lack of actual financial data or transcript content.
2023-01-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.